| Literature DB >> 34531959 |
Joseph E Pero1, John J McAtee1, David J Behm1, Jacques Briand1, Grazyna Graczyk-Millbrandt1, Karl Erhard1, Andrew D Roberts1, Ralph A Rivero1, Dennis A Holt1, Brian G Lawhorn1.
Abstract
GSK2798745, an antagonist of the transient receptor potential vanilloid 4 (TRPV4) ion channel, was recently investigated in clinical trials for the treatment of cardiac and respiratory diseases. Human plasma and urine samples collected from healthy volunteers following oral administration were analyzed to identify circulating and excreted metabolites of the parent drug. One major circulating metabolite (1) was found in pooled human plasma samples, accounting for approximately half of the observed drug-related material. Isolation of metabolite 1 from urine samples followed by MS and NMR studies led to a putative structural assignment of 1 where hydroxylation of GSK2798745 occurred on the central ring, producing a penta-substituted cyclohexane structure containing three stereocenters. Two unique chemical syntheses of the proposed structure were developed to confirm the identity of metabolite 1 and provide access to gram quantities for biological characterization.Entities:
Year: 2021 PMID: 34531959 PMCID: PMC8436415 DOI: 10.1021/acsmedchemlett.1c00406
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.632